REGENERON PHARMACEUTICALS, INC. Quarterly Employee-related Liabilities, Current in USD from Q4 2010 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Summary
Regeneron Pharmaceuticals, Inc. quarterly Employee-related Liabilities, Current history and growth rate from Q4 2010 to Q4 2023.
  • Regeneron Pharmaceuticals, Inc. Employee-related Liabilities, Current for the quarter ending December 31, 2023 was $618M, a 24.3% increase year-over-year.
Employee-related Liabilities, Current, Quarterly (USD)
Employee-related Liabilities, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $618M +$121M +24.3% Dec 31, 2023 10-K 2024-02-05
Q4 2022 $497M +$56.6M +12.8% Dec 31, 2022 10-K 2024-02-05
Q4 2021 $441M -$25.1M -5.39% Dec 31, 2021 10-K 2023-02-06
Q4 2020 $466M +$121M +35.3% Dec 31, 2020 10-K 2022-02-07
Q4 2019 $344M +$82.6M +31.6% Dec 31, 2019 10-K 2021-02-08
Q4 2018 $262M +$70M +36.5% Dec 31, 2018 10-K 2020-02-07
Q4 2017 $192M +$38.7M +25.3% Dec 31, 2017 10-K 2019-02-07
Q3 2017 $166M +$26.4M +18.9% Sep 30, 2017 10-Q 2017-11-08
Q2 2017 $146M +$31.8M +27.8% Jun 30, 2017 10-Q 2017-08-03
Q1 2017 $94.1M +$1.42M +1.53% Mar 31, 2017 10-Q 2017-05-04
Q4 2016 $153M +$19.9M +14.9% Dec 31, 2016 10-K 2018-02-08
Q3 2016 $140M +$18.8M +15.5% Sep 30, 2016 10-Q 2016-11-04
Q2 2016 $115M +$31.5M +37.9% Jun 30, 2016 10-Q 2016-08-04
Q1 2016 $92.7M +$28.6M +44.5% Mar 31, 2016 10-Q 2016-05-05
Q4 2015 $133M +$40.4M +43.6% Dec 31, 2015 10-K 2017-02-09
Q3 2015 $121M +$45.8M +60.9% Sep 30, 2015 10-Q 2015-11-04
Q2 2015 $83.1M +$31.3M +60.5% Jun 30, 2015 10-Q 2015-08-04
Q1 2015 $64.1M +$22.4M +53.5% Mar 31, 2015 10-Q 2015-05-07
Q4 2014 $92.8M +$23.3M +33.6% Dec 31, 2014 10-K 2016-02-11
Q3 2014 $75.2M +$6.23M +9.04% Sep 30, 2014 10-Q 2014-11-04
Q2 2014 $51.8M +$12M +30.2% Jun 30, 2014 10-Q 2014-08-05
Q1 2014 $41.8M +$9.37M +28.9% Mar 31, 2014 10-Q 2014-05-08
Q4 2013 $69.4M +$49.4M +247% Dec 31, 2013 10-K 2015-02-12
Q3 2013 $68.9M +$22.3M +47.9% Sep 30, 2013 10-Q 2013-11-05
Q2 2013 $39.8M +$4.3M +12.1% Jun 30, 2013 10-Q 2013-08-06
Q1 2013 $32.4M -$1.95M -5.68% Mar 31, 2013 10-Q 2013-05-03
Q4 2012 $20M -$22.8M -53.3% Dec 31, 2012 10-K 2014-02-13
Q3 2012 $46.6M +$9M +23.9% Sep 30, 2012 10-Q 2012-10-24
Q2 2012 $35.5M +$9.43M +36.2% Jun 30, 2012 10-Q 2012-07-25
Q1 2012 $34.3M Mar 31, 2012 10-Q 2012-04-26
Q4 2011 $42.8M +$30.8M +256% Dec 31, 2011 10-K 2013-02-15
Q3 2011 $37.6M Sep 30, 2011 10-Q 2011-10-27
Q2 2011 $26M Jun 30, 2011 10-Q 2011-07-28
Q4 2010 $12M Dec 31, 2010 10-K 2012-02-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.